Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + anlotinib + doublet chemotherapy for first-line advanced malignant pleural mesothelioma
ChiCTR2200055419Phase 2Suspended
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and anlotinib in pleural mesothelioma, sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective response rate. Started Nov 2021; status: suspended.
02
Drugs
sintilimabanlotinib
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on ChiCTR2200055419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055419.